ライフサイエンスコーパス: CMV viremia

1 of which can predict risk of progression to CMV viremia.

2 trols, suggesting an APC defect during acute CMV viremia.

3 ts, 23% (13 of 56) of those with significant CMV viremia.

4 (92%) occurred in patents without antecedent CMV viremia.

5 C, hemoglobin <10 g/dL, lower CD4 count, and CMV viremia.

6 sity of immunosuppression after diagnosis of CMV viremia.

7 rom January 2007 to June 2011 for BKV and/or CMV viremia.

8 f worse outcomes in patients with late-onset CMV viremia.

9 0.02) were associated with a higher risk of CMV viremia.

10 stitution of thymopoiesis, but fail to clear CMV viremia.

11 broadened over time despite the clearance of CMV viremia.

12 Twenty-three percent of patients developed CMV viremia.

13 December 2013; 32 (32%) tested positive for CMV viremia.

14 patient developed CMV-T cell responses post-CMV viremia.

15 T; group 2 comprised the 35 patients without CMV viremia.

16 uperior to conventional monitoring to detect CMV viremia.

17 roviral therapy (HAART) led to a decrease in CMV viremia after a 90-day delay.

18 1 consisted of the 8 patients who developed CMV viremia after LT; group 2 comprised the 35 patients

19 No relationship was found between changes in CMV viremia and changes in HIV RNA.

20 t test was used to compare the proportion of CMV viremia and CMV retinitis in patients transplanted b

21 ntly better in the induction group; however, CMV viremia and CMV syndrome rates were significantly hi

22 Donor CMV serostatus had no impact on CMV viremia and disease in the 2 cohorts.

23 CMV viremia and disease occurred in 27% and 4.5%, respec

24 characteristic curve analysis for predicting CMV viremia and disease showed a high area under the rec

25 or cytomegalovirus (CMV) serologic status on CMV viremia and disease when prophylactic granulocyte co

26 bserved; all severe manifestations combined (CMV viremia and disease) were significantly reduced amon

27 The incidence of CMV viremia and of CMV disease was determined during the

28 month period and compare this to the rate of CMV viremia and retinitis in the 4 years prior.

29 aft survival when compared with asymptomatic CMV viremia and those without CMV viremia (relative risk

30 ith valacyclovir also decreased the rates of CMV viremia and viruria, herpes simplex virus disease, a

31 gnificantly higher rates of cytomegalovirus (CMV) viremia and CMV syndrome occurred in those receivin

32 s viridians bacteremia, and cytomegalovirus (CMV) viremia and identified mutations in 2 genes that re

33 man herpesvirus (HHV)-7 and cytomegalovirus (CMV) viremia and the effects of oral and intravenous (iv

34 There was one case of cytomegalovirus (CMV) viremia and two cases of CMV disease (one pneumonit

35 a, (2) immune T-cell recovery anticipated by CMV viremia, and (3) no T-cell immune reconstitution des

36 hich one screens for and treats asymptomatic CMV viremia, and universal antiviral prophylaxis.

37 CMV viremia as detected by PCR does not affect the progr

38 Cytomegalovirus (CMV) viremia, as measured by a hybrid capture assay, was

39 viremia (preemptive, N = 15) or detection of CMV viremia associated with a CMV syndrome (deferred, N

40 Neither patient had CMV viremia before onset of pneumonia.

41 tients, who had been previously analyzed for CMV viremia by polymerase chain reaction (PCR) for 12 we

42 om 35 transplant recipients with and without CMV viremia by using a microarray chip covering 847 hsa-

43 Twenty-five patients had CMV viremia (by shell vial cell culture assay) and/or ti

44 65 that predicted protection from subsequent CMV viremia (concordance index 0.88 [SE, 0.087]).

45 r pre-emptive valganciclovir for significant CMV viremia detected at predefined assessments through m

46 e range, 0.5-197 months) in whom significant CMV viremia developed (CMV level at PCR, >/=4000 copies/

47 CMV viremia did not appear to boost CMV-specific immunit

48 ents after treatment of the first episode of CMV viremia/disease.

49 ral drug resistance should be suspected when CMV viremia (DNAemia or antigenemia) fails to improve or

50 Oral ganciclovir also prevented CMV viremia during prophylaxis (2/19 patients [11%] vs.

51 Time to clearance of CMV viremia during treatment was significantly longer in

52 ne the relationship between cytomegalovirus (CMV) viremia during early infancy and clinical and labor

53 Eighty percent of CMV viremia episodes occurred before 120 days posttransp

54 sidered the "gold standard" for detection of CMV viremia, especially when transport of specimens over

55 t a median of 12 days (range, 3-57 days) and CMV viremia greater than 1000 copies/mL occurred in 20%

56 Moreover, we found that only symptomatic CMV viremia had a significant negative impact on graft s

57 ere sufficient for reactivation of low-level CMV viremia, high-level viremia (>1,000 copies of CMV DN

58 for immunological monitoring and predicting CMV viremia in pediatric HSCT.

59 ), and a CMV plasma PCR for the detection of CMV viremia in renal and bone marrow transplant recipien

60 in a significant and progressive decline in CMV viremia in the absence of specific anti-CMV therapy.

61 In a separate analysis, untreated isolated CMV viremia in the first CMV infection episode was follo

62 CMV viremia in the first year after pediatric primary lu

63 valence and risk factors of cytomegalovirus (CMV) viremia in patients infected with human immunodefic

64 sure to ganciclovir during prophylaxis, with CMV viremia incidence during and after treatment, CMV di

65 g-transplant recipients, we hypothesize that CMV viremia increases the risk of bronchiolitis oblitera

66 ter LT for chronic HCV, patients who develop CMV viremia incur a significantly greater risk of severe

67 We investigated whether short-term CMV viremia influences HCV recurrence, the number and gr

68 The results indicate that CMV viremia is not an ideal marker to guide preemptive a

69 To study whether cytomegalovirus (CMV) viremia is a reliable marker of impending CMV disea

70 CMI assessment shortly after the onset of CMV viremia may be useful to predict progression versus

71 CMV viremia may indirectly protect against subsequent BK

72 Neither CMV viremia nor CMV disease after OLT for HCV-related ci

73 rwent allogeneic HSCT; 13 patients (46%) had CMV viremia, not a statistically significant increase (P

74 CMV viremia occurred in three patients in the acyclovir

75 Clearance of CMV viremia occurs later and depends on the recovery of

76 variable associated with the development of CMV viremia (odds ratio [OR]=1.65; CI 1.03, 2.65) and IT

77 Among 609 recipients, 108 (17.7%) developed CMV viremia, of which 95 (88%) were asymptomatic, 5 (5%)

78 HAART suppressed CMV viremia only after a delay of several months.

79 The primary outcome was recurrence of CMV viremia or disease within 6 months of treatment disc

80 Univariate analysis demonstrated that CMV viremia (P=0.001), invasive fungal disease (P=0.0001

81 nt BKV viremia than patients with antecedent CMV viremia (P=0.003; hazard ratio, 2.05; 95% confidence

82 nts (68%) ultimately showed PCR evidence for CMV viremia (P=0.005).

83 intravenously for 21 days upon detection of CMV viremia (preemptive, N = 15) or detection of CMV vir

84 The observed cytomegalovirus (CMV) viremia rate for patients at risk was low (15%), as

85 h asymptomatic CMV viremia and those without CMV viremia (relative risk, 3.5; 95% confidence interval

86 justment for HIV load and CD4(+) cell count, CMV viremia remained associated with an increased risk o

87 The first episode of CMV viremia requiring antiviral therapy was assessed in

88 e-dependent, Cox proportional hazards model, CMV viremia (RR=8.6, 95% CI 1.8-39.7, P=0.0012), invasiv

89 For CMV viremia, syndrome and disease, the most common first

90 Cytomegalovirus (CMV) viremia that is resistant or refractory to the stan

91 All HSCT recipients with significant CMV viremia underwent retinal examination weekly (inpati

92 Within a same episode, CMV viremia was 90% sensitive and 80% specific for predi

93 Increased CMV viremia was associated with a concomitant fall in Ka

94 ivariate analysis was used to assess whether CMV viremia was associated with BOS or death and retrans

95 In late-stage HIV-infected patients, CMV viremia was associated with lower functional status

96 A first episode of CMV viremia was associated with retransplantation or dea

97 Time to CMV viremia was delayed in the ganciclovir group; howeve

98 CMV viremia was detected by at least one method in 125 o

99 ese Thai patients with advanced HIV disease, CMV viremia was frequent, and CMV DNA >500 copies/mL pre

100 95% CI, 0.09-0.55; P = .001) when persistent CMV viremia was modeled.

101 Initial clearance of CMV viremia was observed in 14 of 17 patients (82%), and

102 The prevalence of CMV viremia was only 5.8% (1-10%).

103 CMV viremia was reduced in every case and eight patients

104 Assessment of CMV viremia was restricted to symptomatic cases in the r

105 The odds of CMV viremia were lower for prophylaxis (OR = 0.42; 95% C

106 y also expanded in the absence of detectable CMV viremia when both the donor and recipient were CMV s

107 Twelve patients experienced CMV viremia, whereas 31 developed CMV disease.

108 Four patients developed CMV viremia with clearance by 1.2 months, which correlat

109 nitiated after a median of three episodes of CMV viremia, with a mean peak viral load of 245,826 copi

110 investigator (investigator treated [IT]), or CMV viremia within 12 months of transplant in D+/R- tran